|
| | 10400SB1238sam001 | - 2 - | LRB104 09624 BDA 23338 a |
|
|
| 1 | | for the treatment of pain, including available nonopioid |
| 2 | | medicinal drugs or drug products and nonpharmacological |
| 3 | | therapies; and |
| 4 | | (2) the advantages and disadvantages of the use of |
| 5 | | nonopioid alternatives. |
| 6 | | Section 10. The Illinois Insurance Code is amended by |
| 7 | | adding Section 370c.3 as follows: |
| 8 | | (215 ILCS 5/370c.3 new) |
| 9 | | Sec. 370c.3. Parity for coverage for nonopioid medications |
| 10 | | to treat acute pain. |
| 11 | | (a) Beginning January 1, 2027, a health insurance issuer |
| 12 | | shall develop a plan to provide adequate coverage and access |
| 13 | | to a broad spectrum of pain management services, including, |
| 14 | | but not limited to, nonopioid, nonnarcotic pain management |
| 15 | | services and non-medication pain management services that |
| 16 | | serve as alternatives to the prescribing of opioid or narcotic |
| 17 | | drugs in accordance with guidelines developed by the |
| 18 | | Department of Insurance. |
| 19 | | (b) A health insurance issuer shall file the plan required |
| 20 | | under subsection (a) with the Department of Insurance and |
| 21 | | shall post information about the pain management plan on the |
| 22 | | insurer's publicly accessible website. |
| 23 | | Section 15. The Illinois Public Aid Code is amended by |
|
| | 10400SB1238sam001 | - 3 - | LRB104 09624 BDA 23338 a |
|
|
| 1 | | adding Section 5-58 as follows: |
| 2 | | (305 ILCS 5/5-58 new) |
| 3 | | Sec. 5-58. Illinois Medicaid Preferred Drug List; |
| 4 | | nonopioid drugs. In establishing and maintaining the Illinois |
| 5 | | Medicaid Preferred Drug List as described in Section 5-30.14, |
| 6 | | the Department shall ensure that nonopioid drugs on the |
| 7 | | Department's preferred drug list, and approved by the U.S. |
| 8 | | Food and Drug Administration, for the treatment or management |
| 9 | | of pain shall not be disadvantaged or discouraged with respect |
| 10 | | to coverage relative to any opioid or narcotic drug for the |
| 11 | | treatment or management of acute pain as long as the |
| 12 | | Department retains its authority to manage the Preferred Drug |
| 13 | | List process pursuant to State or federal law, rules, |
| 14 | | regulations, and policies and the Department's authority over |
| 15 | | the Preferred Drug List process is not undermined or |
| 16 | | compromised.". |